Neuronetics Nears Profitability as Q2 Revenue Hits $41.6M, Loss Narrows
STIM has more than doubled off its 52-week low of $0.8.
Summary
Neuronetics reported Q2 2026 revenue of $41.6 million, up 9.1% year-over-year, beating estimates, driven by a 16.8% jump in Greenbrook clinic revenue to $26.9 million. Adjusted EBITDA swung to a positive $0.3 million from a $5.6 million loss a year ago, and net loss narrowed to $3.4 million from $10.1 million. Gross margin improved to 51.1% from 46.6%, reflecting a new go-to-market strategy and better revenue cycle management. The company also strengthened its leadership team with a new CFO and promotions in the clinic and sales divisions. Cash stood at $25 million at quarter-end, down from $34.1 million at year-end 2025, but cash burn slowed significantly. The results show real progress toward sustained profitability, though the NeuroStar device segment saw a slight revenue dip.
At the time of this announcement, STIM was trading at $2.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $151M. The 52-week trading range was $0.80 to $4.31. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.